View Future GrowthALPEK. de 과거 순이익 실적과거 기준 점검 0/6ALPEK. de 의 수입은 연평균 -52.1%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 1.3%의 비율로 감소했습니다. 매출은 연평균 4.6%의 비율로 감소해 왔습니다.핵심 정보-52.15%순이익 성장률-52.14%주당순이익(EPS) 성장률Chemicals 산업 성장률13.08%매출 성장률-4.57%자기자본이익률-12.81%순이익률-3.34%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.공시 • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026Reported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.공시 • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.공시 • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • May 07Now 21% undervaluedOver the last 90 days, the stock has risen 24% to Mex$12.26. The fair value is estimated to be Mex$15.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 14% to Mex$10.91. The fair value is estimated to be Mex$14.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.공시 • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026공시 • Feb 13ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026. Location: 1111 gomez morin avenue, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey MexicoReported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 5.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (5.6% average weekly change).분석 기사 • Feb 06ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Price Is Out Of Tune With RevenuesWith a median price-to-sales (or "P/S") ratio of close to 0.5x in the Chemicals industry in Mexico, you could be...새로운 내러티브 • Jan 25Tariffs And Footprint Optimization Will Support A Stronger Long Term Earnings MixCatalysts About ALPEK. de Alpek is a petrochemical company with core operations in polyester, plastics and chemicals, focused largely on the North American market.공시 • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026분석 기사 • Jan 10Be Wary Of ALPEK. de (BMV:ALPEKA) And Its Returns On CapitalWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 6.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (6.3% average weekly change).New Risk • Oct 24New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.분석 기사 • Oct 17ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shares have had a really impressive month, gaining 29% after a shaky period...분석 기사 • Oct 06Returns On Capital At ALPEK. de (BMV:ALPEKA) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...공시 • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (4.7% average weekly change).분석 기사 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...Reported Earnings • Jul 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: Mex$0.27 loss per share (down from Mex$0.10 profit in 2Q 2024). Revenue: Mex$32.8b (flat on 2Q 2024). Net loss: Mex$572.0m (down 365% from profit in 2Q 2024). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.공시 • Jun 24ALPEK, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q2, 2025 results on Jul 22, 2025분석 기사 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.Reported Earnings • Apr 23First quarter 2025 earnings released: EPS: Mex$0.081 (vs Mex$0.065 in 1Q 2024)First quarter 2025 results: EPS: Mex$0.081 (up from Mex$0.065 in 1Q 2024). Revenue: Mex$35.0b (up 8.3% from 1Q 2024). Net income: Mex$170.0m (up 24% from 1Q 2024). Profit margin: 0.5% (up from 0.4% in 1Q 2024). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.분석 기사 • Apr 15ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) share price has dived 27% in the last...공시 • Apr 03ALPEK, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q1, 2025 results on Apr 22, 2025Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.분석 기사 • Mar 13Here's Why ALPEK. de (BMV:ALPEKA) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Mar 05ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025. Location: ave gomez morin 1111 south, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey MexicoNew Risk • Feb 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 120% Dividend yield: 19% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • Feb 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Paying a dividend despite being loss-making.분석 기사 • Feb 18Unpleasant Surprises Could Be In Store For ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) SharesIt's not a stretch to say that ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x right now...공시 • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 18, 2025ALPEK, S.A.B. de C.V. announced that they will report Q4, 2024 results on Feb 18, 2025분석 기사 • Jan 30Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Trading At A 48% Discount?Key Insights The projected fair value for ALPEK. de is Mex$27.84 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.분석 기사 • Dec 12Is ALPEK. de (BMV:ALPEKA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (4.7% average weekly change).Reported Earnings • Oct 29Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: EPS: Mex$0.23 (up from Mex$0.21 loss in 3Q 2023). Revenue: Mex$37.2b (up 11% from 3Q 2023). Net income: Mex$483.0m (up Mex$922.8m from 3Q 2023). Profit margin: 1.3% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.공시 • Oct 15ALPEK, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 28, 2024ALPEK, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024분석 기사 • Oct 11Why We're Not Concerned About ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Share PriceWith a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Mexico, you could be...분석 기사 • Sep 12Returns On Capital Signal Difficult Times Ahead For ALPEK. de (BMV:ALPEKA)When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...분석 기사 • Aug 21Should You Investigate ALPEK, S.A.B. de C.V. (BMV:ALPEKA) At Mex$11.86?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not have the largest market cap around , it received a lot of...분석 기사 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...Reported Earnings • Jul 26Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: Mex$0.10 (down from Mex$0.26 in 2Q 2023). Revenue: Mex$33.0b (down 9.0% from 2Q 2023). Net income: Mex$216.0m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.5% in 2Q 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.공시 • Jul 10ALPEK, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024ALPEK, S.A.B. de C.V. announced that they will report Q2, 2024 results on Jul 24, 2024분석 기사 • Jun 21A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.39 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...분석 기사 • Jun 06Some Investors May Be Worried About ALPEK. de's (BMV:ALPEKA) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Buy Or Sell Opportunity • Jun 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 24% to Mex$15.42. The fair value is estimated to be Mex$12.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Meanwhile, the company became loss making.분석 기사 • Apr 25Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS By 51% And Analysts Are Revising Their ForecastsIt's been a good week for ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders, because the company has just released its...Reported Earnings • Apr 24First quarter 2024 earnings released: EPS: Mex$0.065 (vs Mex$0.043 loss in 1Q 2023)First quarter 2024 results: EPS: Mex$0.065 (up from Mex$0.043 loss in 1Q 2023). Revenue: Mex$32.3b (down 16% from 1Q 2023). Net income: Mex$137.0m (up Mex$228.4m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.분석 기사 • Apr 13What ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) P/S Is Not Telling YouThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...공시 • Apr 09ALPEK, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 23, 2024ALPEK, S.A.B. de C.V. announced that they will report Q1, 2024 results on Apr 23, 2024Buy Or Sell Opportunity • Apr 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to Mex$13.22. The fair value is estimated to be Mex$10.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.분석 기사 • Mar 26At Mex$12.61, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a double-digit share price rise...분석 기사 • Mar 08ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Feb 23New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Dividend is not well covered by earnings (371% payout ratio).공시 • Feb 16ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024, at 10:15 Central Standard Time. Location: Avenida Gómez Morín No. 1111 Sur, Colonia Carrizalejo, San Pedro Garza García, Nuevo León Nuevo Leon Mexico Agenda: To consider the Presentation and, as the case may be, approval of the reports referred to in Article 28, section IV, of the Mexican Securities Market Law, relating to the fiscal year 2023; to Proposal on the allocation of the income statement for the fiscal year 2023, which includes the determination of the maximum amount of funds that may be used to purchase the Company’s own stock; to Election of the members of the Board of Directors, as well as the Chairman of the Audit and Corporate Governance Committee; determination of their compensation and related agreements; to Appointment of delegates; to Reading and, as the case may be, approval of the Minutes of the Meeting; and to consider other matters if any.공시 • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 20, 2024ALPEK, S.A.B. de C.V. announced that they will report Q4, 2023 results on Feb 20, 2024분석 기사 • Jan 22A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.26 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...분석 기사 • Jan 04Investor Optimism Abounds ALPEK, S.A.B. de C.V. (BMV:ALPEKA) But Growth Is LackingThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...분석 기사 • Dec 14Is There Now An Opportunity In ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), might not be a large cap stock, but it led the BMV gainers with a relatively...Major Estimate Revision • Nov 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.725 to Mex$0.634 per share. Revenue forecast steady at Mex$142.3b. Net income forecast to grow 392% next year vs 54% growth forecast for Chemicals industry in Mexico. Consensus price target of Mex$22.98 unchanged from last update. Share price was steady at Mex$13.53 over the past week.분석 기사 • Nov 24ALPEK. de (BMV:ALPEKA) Use Of Debt Could Be Considered RiskyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Nov 10Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.753 to Mex$0.603 per share. Revenue forecast steady at Mex$143.2b. Net income forecast to grow 455% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$22.80. Share price was steady at Mex$13.01 over the past week.Major Estimate Revision • Oct 30Consensus EPS estimates fall by 50%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.50 to Mex$0.753 per share. Revenue forecast steady at Mex$144.9b. Net income forecast to grow 554% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target down from Mex$25.47 to Mex$23.53. Share price fell 27% to Mex$10.12 over the past week.Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$10.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry globally. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$16.42 per share.New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Dividend is not well covered by earnings (368% payout ratio). Share price has been volatile over the past 3 months (4.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).Price Target Changed • Oct 25Price target decreased by 7.6% to Mex$23.53Down from Mex$25.47, the current price target is an average from 11 analysts. New target price is 89% above last closing price of Mex$12.47. Stock is down 54% over the past year. The company is forecast to post earnings per share of Mex$0.75 for next year compared to Mex$6.52 last year.Reported Earnings • Oct 24Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: Mex$0.21 loss per share (down from Mex$1.07 profit in 3Q 2022). Revenue: Mex$33.4b (down 44% from 3Q 2022). Net loss: Mex$439.0m (down 120% from profit in 3Q 2022). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Oct 10ALPEK, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 23, 2023ALPEK, S.A.B. de C.V. announced that they will report Q3, 2023 results on Oct 23, 2023Major Estimate Revision • Sep 04Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$143.5b to Mex$142.0b. EPS estimate also fell from Mex$1.59 per share to Mex$1.42 per share. Net income forecast to grow 18% next year vs 31% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.11. Share price was steady at Mex$16.53 over the past week.분석 기사 • Sep 02Is Now The Time To Look At Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...New Risk • Aug 14New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin).Major Estimate Revision • Aug 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.77 to Mex$1.59 per share. Revenue forecast steady at Mex$145.2b. Net income forecast to grow 27% next year vs 25% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.36. Share price was steady at Mex$17.05 over the past week.Price Target Changed • Aug 03Price target decreased by 8.0% to Mex$26.44Down from Mex$28.75, the current price target is an average from 14 analysts. New target price is 51% above last closing price of Mex$17.48. Stock is down 35% over the past year. The company is forecast to post earnings per share of Mex$1.77 for next year compared to Mex$6.52 last year.Major Estimate Revision • Jul 28Consensus EPS estimates increase by 13%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from Mex$157.3b to Mex$150.2b. EPS estimate rose from Mex$2.32 to Mex$2.63. Net income forecast to shrink 46% next year vs 23% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$29.68 to Mex$28.06. Share price was steady at Mex$17.29 over the past week.Reported Earnings • Jul 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: Mex$36.3b (down 36% from 2Q 2022). Net income: Mex$555.0m (down 91% from 2Q 2022). Profit margin: 1.5% (down from 11% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to decline by 2.1% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.분석 기사 • Jul 16ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...공시 • Jul 07ALPEK, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023ALPEK, S.A.B. de C.V. announced that they will report Q2, 2023 results at 11:30 AM, Central Standard Time on Jul 26, 2023분석 기사 • Jun 27ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, ALPEK. de fair value estimate is Mex$32.21 Current share price...Major Estimate Revision • May 10Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$2.73 to Mex$2.42. Revenue forecast unchanged from Mex$163.8b at last update. Net income forecast to shrink 33% next year vs 31% growth forecast for Chemicals industry in Mexico . Consensus price target reaffirmed at Mex$30.61. Share price was steady at Mex$19.28 over the past week.분석 기사 • Apr 30The ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Analysts Have Been Trimming Their Sales ForecastsOne thing we could say about the analysts on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) - they aren't optimistic, having just...Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: Mex$0.043 loss per share (down from Mex$2.23 profit in 1Q 2022). Revenue: Mex$38.6b (down 19% from 1Q 2022). Net loss: Mex$91.0m (down 102% from profit in 1Q 2022). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.분석 기사 • Apr 20When Should You Buy ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...Major Estimate Revision • Mar 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$3.29 to Mex$2.86 per share. Revenue forecast steady at Mex$172.8b. Net income forecast to shrink 55% next year vs 20% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$31.96 to Mex$31.32. Share price fell 4.7% to Mex$20.68 over the past week.분석 기사 • Mar 28An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 34% UndervaluedKey Insights The projected fair value for ALPEK. de is Mex$30.88 based on 2 Stage Free Cash Flow to Equity ALPEK. de is...분석 기사 • Feb 25These Analysts Think ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Sales Are Under ThreatMarket forces rained on the parade of ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders today, when the analysts...Major Estimate Revision • Feb 24Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$194.4b to Mex$174.4b. EPS estimate fell from Mex$4.14 to Mex$3.92 per share. Net income forecast to shrink 38% next year vs 6.5% decline forecast for Chemicals industry in Mexico. Consensus price target down from Mex$35.20 to Mex$33.24. Share price fell 6.1% to Mex$22.24 over the past week.분석 기사 • Feb 23Is ALPEK. de (BMV:ALPEKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Buying Opportunity • Feb 18Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be Mex$30.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to decline by 7.4% per annum. Earnings is also forecast to decline by 29% per annum over the same time period.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to Mex$23.68, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$23.26 per share.공시 • Feb 01ALPEK, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 15, 2023ALPEK, S.A.B. de C.V. announced that they will report Q4, 2022 results on Feb 15, 2023분석 기사 • Jan 07Is It Too Late To Consider Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a decent share price growth in...분석 기사 • Dec 22Estimating The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$30.5 based on 2 Stage Free Cash Flow to Equity Current share price...Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 22Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: Mex$1.07 (up from Mex$1.05 in 3Q 2021). Revenue: Mex$59.8b (up 44% from 3Q 2021). Net income: Mex$2.25b (up 1.2% from 3Q 2021). Profit margin: 3.8% (down from 5.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is expected to fall by 4.7% p.a. on average during the next 3 years compared to a 1.9% decline forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.분석 기사 • Sep 24At Mex$26.92, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw significant share price movement...분석 기사 • Aug 30We Think ALPEK. de (BMV:ALPEKA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Buying Opportunity • Aug 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be Mex$34.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 4.4% per annum. Earnings is also forecast to decline by 37% per annum over the same time period.매출 및 비용 세부 내역ALPEK. de가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BMV:ALPEK A 매출, 비용 및 순이익 (MXN Millions)날짜매출순이익일반관리비연구개발비31 Mar 26121,579-4,0625,457031 Dec 25126,840-2,7745,650030 Sep 25133,745-2,8105,932030 Jun 25139,829-1,5196,276031 Mar 25140,082-7326,217031 Dec 24137,409-7656,088030 Sep 24132,434-10,1035,622030 Jun 24128,647-11,0265,492031 Mar 24131,934-10,6865,668031 Dec 23138,159-10,9145,896030 Sep 23156,6837676,144030 Jun 23183,0653,4536,522031 Mar 23203,1338,9556,846031 Dec 22212,43513,7446,959030 Sep 22208,68913,6027,364030 Jun 22190,59113,5767,042031 Mar 22171,27110,0016,499031 Dec 21156,2247,7566,095030 Sep 21140,2689,1755,673030 Jun 21127,9278,3925,429031 Mar 21118,2976,0285,438031 Dec 20113,9893,1235,440030 Sep 20112,4135,1515,313030 Jun 20112,6624,6915,176031 Mar 20116,6405,6355,083031 Dec 19119,6856,6054,961030 Sep 19127,35410,3735,110030 Jun 19134,62710,9135,221031 Mar 19137,34512,6015,384031 Dec 18134,52313,6335,323030 Sep 18124,7315,2406,892030 Jun 18111,272-3,4066,467031 Mar 18101,404-5,7076,022031 Dec 1798,998-5,4875,884030 Sep 1797,416-4,3663,807030 Jun 1797,1733,6973,831031 Mar 1795,2404,1123,775031 Dec 1690,1923,6253,665030 Sep 1687,1743,5583,630030 Jun 1686,1033,2483,526031 Mar 1685,1613,6543,434031 Dec 1583,5902,7483,247030 Sep 1585,9811,8443,046030 Jun 1585,3311,6152,8660양질의 수익: ALPEK A 은(는) 현재 수익성이 없습니다.이익 마진 증가: ALPEK A는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ALPEK A은 수익성이 없으며 지난 5년 동안 손실이 연평균 52.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ALPEK A의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ALPEK A은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-10.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ALPEK A는 현재 수익성이 없으므로 자본 수익률이 음수(-12.81%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 02:16종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ALPEK, S.A.B. de C.V.는 16명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gilberto GarciaBarclaysPablo Monsivais MendozaBarclaysLeonardo MarcondesBofA Global Research13명의 분석가 더 보기
Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
공시 • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
Reported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
공시 • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026
Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
공시 • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025
Buy Or Sell Opportunity • May 07Now 21% undervaluedOver the last 90 days, the stock has risen 24% to Mex$12.26. The fair value is estimated to be Mex$15.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 14% to Mex$10.91. The fair value is estimated to be Mex$14.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.
공시 • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
공시 • Feb 13ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026. Location: 1111 gomez morin avenue, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico
Reported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 5.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (5.6% average weekly change).
분석 기사 • Feb 06ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Price Is Out Of Tune With RevenuesWith a median price-to-sales (or "P/S") ratio of close to 0.5x in the Chemicals industry in Mexico, you could be...
새로운 내러티브 • Jan 25Tariffs And Footprint Optimization Will Support A Stronger Long Term Earnings MixCatalysts About ALPEK. de Alpek is a petrochemical company with core operations in polyester, plastics and chemicals, focused largely on the North American market.
공시 • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026
분석 기사 • Jan 10Be Wary Of ALPEK. de (BMV:ALPEKA) And Its Returns On CapitalWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 6.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (6.3% average weekly change).
New Risk • Oct 24New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
분석 기사 • Oct 17ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shares have had a really impressive month, gaining 29% after a shaky period...
분석 기사 • Oct 06Returns On Capital At ALPEK. de (BMV:ALPEKA) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
공시 • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025
New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (4.7% average weekly change).
분석 기사 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...
Reported Earnings • Jul 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: Mex$0.27 loss per share (down from Mex$0.10 profit in 2Q 2024). Revenue: Mex$32.8b (flat on 2Q 2024). Net loss: Mex$572.0m (down 365% from profit in 2Q 2024). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
공시 • Jun 24ALPEK, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q2, 2025 results on Jul 22, 2025
분석 기사 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...
Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.
Reported Earnings • Apr 23First quarter 2025 earnings released: EPS: Mex$0.081 (vs Mex$0.065 in 1Q 2024)First quarter 2025 results: EPS: Mex$0.081 (up from Mex$0.065 in 1Q 2024). Revenue: Mex$35.0b (up 8.3% from 1Q 2024). Net income: Mex$170.0m (up 24% from 1Q 2024). Profit margin: 0.5% (up from 0.4% in 1Q 2024). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
분석 기사 • Apr 15ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) share price has dived 27% in the last...
공시 • Apr 03ALPEK, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q1, 2025 results on Apr 22, 2025
Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.
분석 기사 • Mar 13Here's Why ALPEK. de (BMV:ALPEKA) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Mar 05ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025. Location: ave gomez morin 1111 south, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico
New Risk • Feb 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 120% Dividend yield: 19% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • Feb 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Paying a dividend despite being loss-making.
분석 기사 • Feb 18Unpleasant Surprises Could Be In Store For ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) SharesIt's not a stretch to say that ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x right now...
공시 • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 18, 2025ALPEK, S.A.B. de C.V. announced that they will report Q4, 2024 results on Feb 18, 2025
분석 기사 • Jan 30Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Trading At A 48% Discount?Key Insights The projected fair value for ALPEK. de is Mex$27.84 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.
분석 기사 • Dec 12Is ALPEK. de (BMV:ALPEKA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (4.7% average weekly change).
Reported Earnings • Oct 29Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: EPS: Mex$0.23 (up from Mex$0.21 loss in 3Q 2023). Revenue: Mex$37.2b (up 11% from 3Q 2023). Net income: Mex$483.0m (up Mex$922.8m from 3Q 2023). Profit margin: 1.3% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
공시 • Oct 15ALPEK, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 28, 2024ALPEK, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024
분석 기사 • Oct 11Why We're Not Concerned About ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Share PriceWith a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Mexico, you could be...
분석 기사 • Sep 12Returns On Capital Signal Difficult Times Ahead For ALPEK. de (BMV:ALPEKA)When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
분석 기사 • Aug 21Should You Investigate ALPEK, S.A.B. de C.V. (BMV:ALPEKA) At Mex$11.86?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not have the largest market cap around , it received a lot of...
분석 기사 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...
Reported Earnings • Jul 26Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: Mex$0.10 (down from Mex$0.26 in 2Q 2023). Revenue: Mex$33.0b (down 9.0% from 2Q 2023). Net income: Mex$216.0m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.5% in 2Q 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
공시 • Jul 10ALPEK, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024ALPEK, S.A.B. de C.V. announced that they will report Q2, 2024 results on Jul 24, 2024
분석 기사 • Jun 21A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.39 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
분석 기사 • Jun 06Some Investors May Be Worried About ALPEK. de's (BMV:ALPEKA) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Buy Or Sell Opportunity • Jun 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 24% to Mex$15.42. The fair value is estimated to be Mex$12.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Meanwhile, the company became loss making.
분석 기사 • Apr 25Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS By 51% And Analysts Are Revising Their ForecastsIt's been a good week for ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders, because the company has just released its...
Reported Earnings • Apr 24First quarter 2024 earnings released: EPS: Mex$0.065 (vs Mex$0.043 loss in 1Q 2023)First quarter 2024 results: EPS: Mex$0.065 (up from Mex$0.043 loss in 1Q 2023). Revenue: Mex$32.3b (down 16% from 1Q 2023). Net income: Mex$137.0m (up Mex$228.4m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
분석 기사 • Apr 13What ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) P/S Is Not Telling YouThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...
공시 • Apr 09ALPEK, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 23, 2024ALPEK, S.A.B. de C.V. announced that they will report Q1, 2024 results on Apr 23, 2024
Buy Or Sell Opportunity • Apr 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to Mex$13.22. The fair value is estimated to be Mex$10.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
분석 기사 • Mar 26At Mex$12.61, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a double-digit share price rise...
분석 기사 • Mar 08ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Feb 23New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Dividend is not well covered by earnings (371% payout ratio).
공시 • Feb 16ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024, at 10:15 Central Standard Time. Location: Avenida Gómez Morín No. 1111 Sur, Colonia Carrizalejo, San Pedro Garza García, Nuevo León Nuevo Leon Mexico Agenda: To consider the Presentation and, as the case may be, approval of the reports referred to in Article 28, section IV, of the Mexican Securities Market Law, relating to the fiscal year 2023; to Proposal on the allocation of the income statement for the fiscal year 2023, which includes the determination of the maximum amount of funds that may be used to purchase the Company’s own stock; to Election of the members of the Board of Directors, as well as the Chairman of the Audit and Corporate Governance Committee; determination of their compensation and related agreements; to Appointment of delegates; to Reading and, as the case may be, approval of the Minutes of the Meeting; and to consider other matters if any.
공시 • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 20, 2024ALPEK, S.A.B. de C.V. announced that they will report Q4, 2023 results on Feb 20, 2024
분석 기사 • Jan 22A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.26 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
분석 기사 • Jan 04Investor Optimism Abounds ALPEK, S.A.B. de C.V. (BMV:ALPEKA) But Growth Is LackingThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...
분석 기사 • Dec 14Is There Now An Opportunity In ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), might not be a large cap stock, but it led the BMV gainers with a relatively...
Major Estimate Revision • Nov 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.725 to Mex$0.634 per share. Revenue forecast steady at Mex$142.3b. Net income forecast to grow 392% next year vs 54% growth forecast for Chemicals industry in Mexico. Consensus price target of Mex$22.98 unchanged from last update. Share price was steady at Mex$13.53 over the past week.
분석 기사 • Nov 24ALPEK. de (BMV:ALPEKA) Use Of Debt Could Be Considered RiskyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Nov 10Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.753 to Mex$0.603 per share. Revenue forecast steady at Mex$143.2b. Net income forecast to grow 455% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$22.80. Share price was steady at Mex$13.01 over the past week.
Major Estimate Revision • Oct 30Consensus EPS estimates fall by 50%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.50 to Mex$0.753 per share. Revenue forecast steady at Mex$144.9b. Net income forecast to grow 554% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target down from Mex$25.47 to Mex$23.53. Share price fell 27% to Mex$10.12 over the past week.
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$10.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry globally. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$16.42 per share.
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Dividend is not well covered by earnings (368% payout ratio). Share price has been volatile over the past 3 months (4.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).
Price Target Changed • Oct 25Price target decreased by 7.6% to Mex$23.53Down from Mex$25.47, the current price target is an average from 11 analysts. New target price is 89% above last closing price of Mex$12.47. Stock is down 54% over the past year. The company is forecast to post earnings per share of Mex$0.75 for next year compared to Mex$6.52 last year.
Reported Earnings • Oct 24Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: Mex$0.21 loss per share (down from Mex$1.07 profit in 3Q 2022). Revenue: Mex$33.4b (down 44% from 3Q 2022). Net loss: Mex$439.0m (down 120% from profit in 3Q 2022). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Oct 10ALPEK, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 23, 2023ALPEK, S.A.B. de C.V. announced that they will report Q3, 2023 results on Oct 23, 2023
Major Estimate Revision • Sep 04Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$143.5b to Mex$142.0b. EPS estimate also fell from Mex$1.59 per share to Mex$1.42 per share. Net income forecast to grow 18% next year vs 31% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.11. Share price was steady at Mex$16.53 over the past week.
분석 기사 • Sep 02Is Now The Time To Look At Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...
New Risk • Aug 14New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin).
Major Estimate Revision • Aug 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.77 to Mex$1.59 per share. Revenue forecast steady at Mex$145.2b. Net income forecast to grow 27% next year vs 25% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.36. Share price was steady at Mex$17.05 over the past week.
Price Target Changed • Aug 03Price target decreased by 8.0% to Mex$26.44Down from Mex$28.75, the current price target is an average from 14 analysts. New target price is 51% above last closing price of Mex$17.48. Stock is down 35% over the past year. The company is forecast to post earnings per share of Mex$1.77 for next year compared to Mex$6.52 last year.
Major Estimate Revision • Jul 28Consensus EPS estimates increase by 13%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from Mex$157.3b to Mex$150.2b. EPS estimate rose from Mex$2.32 to Mex$2.63. Net income forecast to shrink 46% next year vs 23% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$29.68 to Mex$28.06. Share price was steady at Mex$17.29 over the past week.
Reported Earnings • Jul 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: Mex$36.3b (down 36% from 2Q 2022). Net income: Mex$555.0m (down 91% from 2Q 2022). Profit margin: 1.5% (down from 11% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to decline by 2.1% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
분석 기사 • Jul 16ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
공시 • Jul 07ALPEK, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023ALPEK, S.A.B. de C.V. announced that they will report Q2, 2023 results at 11:30 AM, Central Standard Time on Jul 26, 2023
분석 기사 • Jun 27ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, ALPEK. de fair value estimate is Mex$32.21 Current share price...
Major Estimate Revision • May 10Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$2.73 to Mex$2.42. Revenue forecast unchanged from Mex$163.8b at last update. Net income forecast to shrink 33% next year vs 31% growth forecast for Chemicals industry in Mexico . Consensus price target reaffirmed at Mex$30.61. Share price was steady at Mex$19.28 over the past week.
분석 기사 • Apr 30The ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Analysts Have Been Trimming Their Sales ForecastsOne thing we could say about the analysts on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) - they aren't optimistic, having just...
Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: Mex$0.043 loss per share (down from Mex$2.23 profit in 1Q 2022). Revenue: Mex$38.6b (down 19% from 1Q 2022). Net loss: Mex$91.0m (down 102% from profit in 1Q 2022). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
분석 기사 • Apr 20When Should You Buy ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...
Major Estimate Revision • Mar 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$3.29 to Mex$2.86 per share. Revenue forecast steady at Mex$172.8b. Net income forecast to shrink 55% next year vs 20% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$31.96 to Mex$31.32. Share price fell 4.7% to Mex$20.68 over the past week.
분석 기사 • Mar 28An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 34% UndervaluedKey Insights The projected fair value for ALPEK. de is Mex$30.88 based on 2 Stage Free Cash Flow to Equity ALPEK. de is...
분석 기사 • Feb 25These Analysts Think ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Sales Are Under ThreatMarket forces rained on the parade of ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders today, when the analysts...
Major Estimate Revision • Feb 24Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$194.4b to Mex$174.4b. EPS estimate fell from Mex$4.14 to Mex$3.92 per share. Net income forecast to shrink 38% next year vs 6.5% decline forecast for Chemicals industry in Mexico. Consensus price target down from Mex$35.20 to Mex$33.24. Share price fell 6.1% to Mex$22.24 over the past week.
분석 기사 • Feb 23Is ALPEK. de (BMV:ALPEKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Buying Opportunity • Feb 18Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be Mex$30.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to decline by 7.4% per annum. Earnings is also forecast to decline by 29% per annum over the same time period.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to Mex$23.68, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$23.26 per share.
공시 • Feb 01ALPEK, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 15, 2023ALPEK, S.A.B. de C.V. announced that they will report Q4, 2022 results on Feb 15, 2023
분석 기사 • Jan 07Is It Too Late To Consider Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a decent share price growth in...
분석 기사 • Dec 22Estimating The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$30.5 based on 2 Stage Free Cash Flow to Equity Current share price...
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 22Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: Mex$1.07 (up from Mex$1.05 in 3Q 2021). Revenue: Mex$59.8b (up 44% from 3Q 2021). Net income: Mex$2.25b (up 1.2% from 3Q 2021). Profit margin: 3.8% (down from 5.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is expected to fall by 4.7% p.a. on average during the next 3 years compared to a 1.9% decline forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
분석 기사 • Sep 24At Mex$26.92, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw significant share price movement...
분석 기사 • Aug 30We Think ALPEK. de (BMV:ALPEKA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Buying Opportunity • Aug 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be Mex$34.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 4.4% per annum. Earnings is also forecast to decline by 37% per annum over the same time period.
